Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).

Biotechnology

Education

Appia Bio

JJ Kang

Sylvaine Cases

Monica Jenkins

Alex Babayan

Tessa Aglupos-McCann

David Moskowitz

Jeff Wiezorek

Edmund Kim

Jason Damiano

The Scientific Team at Appia Bio is dedicated to advancing the company's mission of developing allogeneic cell therapies. This team conducts cutting-edge research and development using the ACUA technology platform, working on the genetic engineering of CAR-iNKT cells from HSCs. They collaborate on designing, executing, and analyzing experiments to discover novel cell therapies, with a focus on improving the effectiveness and scalability of these treatments to increase patient access across various medical indications.

Scientific Team

Leadership Team

Scientific Team

About

Team members

Other teams at Appia Bio

Leadership Team